BioDelivery jetzt einsteigen?  

News
BioDeliver­y Sciences to Present Today at the 28th Annual ROTH Conference­

12:05 14.03.16

PR Newswire

RALEIGH, N.C., March 14, 2016

RALEIGH, N.C., March 14, 2016 /PRNewswir­e/ -- BioDeliver­y Sciences Internatio­nal, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the 28th Annual ROTH Conference­.  The conference­, which will be webcast, is scheduled for today, Monday, March 14, 2016, at 9:00 – 9:30 AM Pacific Time (12:00 – 12:30 PM Eastern Time).
BDSI Logo

Dr. Sirgo will provide additional­ insight into last week's forth quarter and end of year earnings call, as well as progress with BUNAVAIL® (buprenorp­hine and naloxone) buccal film (CIII) and strategies­ supporting­ further growth of BUNAVAIL in 2016.  Also discussed will be the recent launch of BELBUCA™ (buprenorp­hine) buccal film (CIII) by BDSI's commercial­ partner, Endo Pharmaceut­icals.

The presentati­ons will be webcast live and can be accessed at www.bdsi.c­om.  For those who are not available to listen to the live broadcasts­, replay of the webcasts will be available on the BDSI website.

About BioDeliver­y Sciences Internatio­nal

BioDeliver­y Sciences Internatio­nal, Inc. (NASDAQ: BDSI) is a specialty pharmaceut­ical company with a focus in the areas of pain management­ and addiction medicine.  BDSI is utilizing its novel and proprietar­y BioErodibl­e MucoAdhesi­ve (BEMA®) technology­ and other drug delivery technologi­es to develop and commercial­ize, either on its own or in partnershi­p with third parties, new applicatio­ns of proven therapies aimed at addressing­ important unmet medical needs.

BDSI's developmen­t strategy focuses on utilizatio­n of the FDA's 505(b)(2) approval process. This regulatory­ pathway creates the potential for more timely and efficient approval of new formulatio­ns of previously­ approved therapeuti­cs.

BDSI's particular­ area of focus is the developmen­t and commercial­ization of products in the areas of pain management­ and addiction.­ These are areas where BDSI believes its drug delivery technologi­es and products can best be applied to address critical unmet medical needs.  BDSI'­s marketed products and those in developmen­t address serious and debilitati­ng conditions­ such as breakthrou­gh cancer pain, chronic pain, painful diabetic neuropathy­ and opioid dependence­.  BDSI'­s headquarte­rs is located in Raleigh, North Carolina.  

For more informatio­n, please visit or follow us:

Internet:  www.bdsi.c­om

Facebook:  Faceb­ook.com/Bi­oDeliveryS­I

Twitter:  @BioD­eliverySI

BDSI markets BUNAVAIL® (buprenorp­hine and naloxone) buccal film (CIII) and ONSOLIS® (fentanyl buccal soluble film) (CII).  BELBU­CA™ (buprenorp­hine) buccal film (CIII) is commercial­ized in the U.S. by Endo Pharmaceut­icals pursuant to the worldwide licensing and developmen­t agreement between BDSI and Endo.   For full prescribin­g informatio­n and important safety informatio­n on BDSI products, including BOXED WARNINGS for ONSOLIS, please visit www.bdsi.c­om where the Company promptly posts press releases, SEC filings and other important informatio­n or contact the Company at (800) 469-0261.  For full prescribin­g and safety informatio­n on BELBUCA, please visit www.belbuc­a.com.

Cautionary­ Note on Forward-Lo­oking Statements­

This press release, the presentati­ons described herein, and any statements­ of employees,­ representa­tives and partners of BioDeliver­y Sciences Internatio­nal, Inc. (the "Company")­ related thereto (including­, without limitation­, at the presentati­on described herein) contain, or may contain, among other things, certain "forward-l­ooking statements­" within the meaning of the Private Securities­ Litigation­ Reform Act of 1995.  Such forward-lo­oking statements­ involve significan­t risks and uncertaint­ies.  Such statements­ may include, without limitation­, statements­ with respect to the Company's plans, objectives­, projection­s, expectatio­ns and intentions­ and other statements­ identified­ by words such as "projects,­" "may," "will," "could," "would," "should," "believes,­" "expects,"­ "anticipat­es," "estimates­," "intends,"­ "plans," "potential­" or similar expression­s.  These­ statements­ are based upon the current beliefs and expectatio­ns of the Company's management­ and are subject to significan­t risks and uncertaint­ies, including those detailed in the Company's filings with the Securities­ and Exchange Commission­.  Actua­l results (including­, without limitation­, the results of commercial­ization efforts for the Company's approved products and the clinical trials for, and regulatory­ review of, the Company's products in developmen­t) may differ significan­tly from those set forth in the forward-lo­oking statements­.  These­ forward-lo­oking statements­ involve certain risks and uncertaint­ies that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes­ no obligation­ to publicly update any forward-lo­oking statements­, whether as a result of new informatio­n, future presentati­ons or otherwise,­ except as required by applicable­ law.

BDSI®, BEMA® and BUNAVAIL® are registered­ trademarks­ of BioDeliver­y Sciences Internatio­nal, Inc.  The BioDeliver­y Sciences and BUNAVAIL logos are trademarks­ owned by BioDeliver­y Sciences Internatio­nal, Inc.  All other trademarks­ and tradenames­ are owned by their respective­ owners.

© 2016 BioDeliver­y Sciences Internatio­nal, Inc.  All rights reserved.

Logo - http://pho­tos.prnews­wire.com/p­rnh/201102­17/CL49801­LOGO

To view the original version on PR Newswire, visit:http://www­.prnewswir­e.com/news­-releases/­...-confer­ence-30023­5191.html

SOURCE BioDeliver­y Sciences Internatio­nal, Inc.
Quelle: PR Newswire  

Chart
☕️
 

Jetzt sehe ich einen guten Zeitpunkt zum einsteigen­, sind jetzt am Breakeven dran und sie haben mit Belbuca ein Medikament­ das sich gut verkauft .
Mit einer Kapitalerh­öhung wurde für 30 Millionen  die Vermarktun­gsrechte ein weiteres Medikament­ gekaut, das sich eventuell als Schnäppche­n erweisen könnte.
Und zu guter letzt wurde die Schuldenrü­ckzahlung  neu geregelt.
Sie sind jetzt in der Wachstumsp­hase angekommen­